Ranbaxy gets 180 days of exclusivity for Aricept generic

09/21/2010 | Bloomberg

India-based Ranbaxy Laboratories won exclusive rights to sell a generic version of Eisai Co.'s Alzheimer's drug Aricept. The FDA said Teva Pharmaceutical Industries, which had an approval to sell the drug, must delay 180 days before competing with Ranbaxy.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI